Cefdinir
FDA-approved product (capsule, oral), marketed as Cefdinir, Omnicef.
- Registered studies
- 32
- Lab records
- 8
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Chronic bronchitis
- Infection
- Infectious otitis media
- Otitis media
- Pharyngitis
- Pneumonia
- Recurrent tonsillitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Third-generation cephalosporins
- FDA pharmacologic class
- Cephalosporin Antibacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DD15; FDA class Cephalosporin Antibacterial
Repurposing investigation
Cefdinir is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli99.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis47.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
32registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
- E. coli: measured active in 4 of 4 lab records
- K. pneumoniae: measured active in 2 of 2 lab records
Show the 8 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cefdinir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT06406114 · start 2025-05-05
Registered record
- Registry ID
- NCT06406114
- Conditions
- Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
- Interventions
- Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-05-05
- Completion
- 2028-12-31
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 moreInterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 morePhasePhase 2Registry statusRecruitingSingle Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting
NCT05702762 · start 2022-10-01
Registered record
- Registry ID
- NCT05702762
- Conditions
- Urinary Tract Infections
- Interventions
- Gentamicin; Standard of Care
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-10-01
- Completion
- 2024-06-30
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary Tract InfectionsInterventionGentamicin; Standard of CarePhasePhase 2Registry statusUnknownPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404 · start 2020-03-05
Registered record
- Registry ID
- NCT04278404
- Conditions
- Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2020-03-05
- Completion
- 2026-12
- Enrolment
- 5,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 moreInterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:PhaseNot recordedRegistry statusRecruitingThe Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis
NCT03756324 · start 2018-12-20
Registered record
- Registry ID
- NCT03756324
- Conditions
- Mastitis Acute Female
- Interventions
- CHPM (Chinese Herbal Patent Medicine ); Antibiotics Cefdinir Capsules; Education; Antibiotics Cefdinir Capsules
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Unknown
- Start
- 2018-12-20
- Completion
- 2021-03-31
- Enrolment
- 306
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMastitis Acute FemaleInterventionCHPM (Chinese Herbal Patent Medicine ); Antibiotics Cefdinir Capsules; Education; Antibiotics Cefdinir CapsulesPhasePhase 2 / Phase 3Registry statusUnknownComparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults
NCT03400735 · start 2017-11-01
Registered record
- Registry ID
- NCT03400735
- Conditions
- Acute Exacerbation of Chronic Bronchitis; Community-Acquired Pneumoniae
- Interventions
- Cefdinir/clavulanic acide 300/125 mg film-coated tablets; Cefdinir 300Mg Capsule
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2017-11-01
- Completion
- 2018-08-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Exacerbation of Chronic Bronchitis; Community-Acquired PneumoniaeInterventionCefdinir/clavulanic acide 300/125 mg film-coated tablets; Cefdinir 300Mg CapsulePhasePhase 4Registry statusUnknownProphylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
NCT03014687 · start 2017-07-01
Registered record
- Registry ID
- NCT03014687
- Conditions
- Antibiotics; Pituitary Adenoma
- Interventions
- Placebo; Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2017-07-01
- Completion
- 2019-07
- Enrolment
- 116
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAntibiotics; Pituitary AdenomaInterventionPlacebo; Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazolePhasePhase 4Registry statusRecruitingTrial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
NCT02891915 · start 2016-12-02
Registered record
- Registry ID
- NCT02891915
- Conditions
- Pneumonia
- Interventions
- Amoxicillin; Amoxicillin-clavulanate; Cefdinir; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-12-02
- Completion
- 2019-12-16
- Enrolment
- 385
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPneumoniaInterventionAmoxicillin; Amoxicillin-clavulanate; Cefdinir; PlaceboPhasePhase 4Registry statusCompletedSafety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis
NCT04664803 · start 2015-08-31
Registered record
- Registry ID
- NCT04664803
- Conditions
- Acute Sinusitis
- Interventions
- Cefecin Tab.; Omnicef Cap.
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2015-08-31
- Completion
- 2019-08-31
- Enrolment
- 284
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute SinusitisInterventionCefecin Tab.; Omnicef Cap.PhasePhase 4Registry statusTerminatedPilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis
NCT02447224 · start 2015-03
Registered record
- Registry ID
- NCT02447224
- Conditions
- Acute Uncomplicated Appendicitis
- Interventions
- 1 gm IV ertapenem at enrollment; 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days; Appendectomy
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2015-03
- Completion
- 2017-12-31
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Uncomplicated AppendicitisIntervention1 gm IV ertapenem at enrollment; 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days; AppendectomyPhaseEarly phase 1Registry statusCompletedPatients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminatedComparative Effectiveness of Antibiotics for Respiratory Infections
NCT02297815 · start 2014-01
Registered record
- Registry ID
- NCT02297815
- Conditions
- Acute Otitis Media; Acute Sinusitis; Group A Streptococcal Pharyngitis
- Interventions
- Broad-spectrum antibiotics; Narrow-spectrum antibiotics
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-01
- Completion
- 2016-04
- Enrolment
- 2,472
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Otitis Media; Acute Sinusitis; Group A Streptococcal PharyngitisInterventionBroad-spectrum antibiotics; Narrow-spectrum antibioticsPhaseNot recordedRegistry statusCompletedInfluence of Medication Taste on Pediatric Prescribers' Prescribing Habits
NCT01734759 · start 2012-11
Registered record
- Registry ID
- NCT01734759
- Conditions
- Healthy
- Interventions
- Taste Test
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-11
- Completion
- 2013-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionTaste TestPhasePhase 1Registry statusCompletedThe SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
NCT01595529 · start 2012-05-18
Registered record
- Registry ID
- NCT01595529
- Conditions
- Urinary Tract Infection
- Interventions
- Cefixime; Cephalexin; Placebo; Trimethoprim/Sulfamethoxazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-05-18
- Completion
- 2019-08-12
- Enrolment
- 717
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrinary Tract InfectionInterventionCefixime; Cephalexin; Placebo; Trimethoprim/SulfamethoxazolePhasePhase 2Registry statusCompletedComparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use
NCT01561703 · start 2012-03
Registered record
- Registry ID
- NCT01561703
- Conditions
- Snoring; Strep Throat
- Interventions
- Antibiotic
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2015-06
- Enrolment
- 58
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSnoring; Strep ThroatInterventionAntibioticPhaseNot applicableRegistry statusCompletedEffectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
NCT01000298 · start 2009-12
Registered record
- Registry ID
- NCT01000298
- Conditions
- Kwashiorkor; Marasmus
- Interventions
- Placebo; Amoxicillin; Cefdinir
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-12
- Completion
- 2011-05
- Enrolment
- 2,767
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKwashiorkor; MarasmusInterventionPlacebo; Amoxicillin; CefdinirPhaseNot applicableRegistry statusCompleted